News

Takeda has submitted a supplemental new drug application to the Ministry of Health, Welfare and Labour in Japan for Takepron Capsules 15 and Takepron OD tablet 15 (lansoprazole)

Karo Bio has announced that Merck & Co. plans to enter a clinical phase IIa trial with the investigational drug candidate, MK-6913, identified as part of their joint

Merck & Co., through an affiliate, has extended its research collaboration with Idera for a fourth year. In December 2006, the companies entered into an exclusive license and

Genfit has reported positive results in Phase II trial with its most advanced drug candidate, GFT505, in prediabetic patients with atherogenic dyslipidemia and abdominal obesity (study GFT505-2083). The

Pfizer Japan (Pfizer) and Astellas Pharma (Astellas) to launch the combination drug of hypertension treatment and hypercholesterolemia treatment Caduet combination tablets (generic name: amlodipine besylate and atorvastatin calcium)

China Sky One Medical has recently passed the Chinese National Institute for the Control of Pharmaceutical and Biological Products (ICPBP) examination for two of its new products –

The FDA has granted traditional approval for Tibotec Therapeutics’ Intelence (etravirine) tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI). Intelence is currently marketed in the US by Tibotec, a

Sinovac Biotech has executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd (Sinovac Dalian). The JV will research, develop, produce and commercialise human-use

Idera Pharmaceuticals and Merck & Co., have extended its research collaboration for a fourth year. In December 2006, the companies entered into an exclusive license and research collaboration